Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2011-06-06 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2011-06-06 English
4 Filing
Director's Dealing
2011-06-03 English
8-K Filing
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 1, 2011, reporting the results of the 2011 annual meeting of stockholders of Ligand Pharmaceuticals Incorporated. It details voting outcomes on board member elections, auditor ratification, executive compensation approval, and frequency of advisory votes on compensation. The content is focused on the submission of matters to a vote of security holders, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4296 characters, which is short but contains substantive voting results, not just an announcement of a report. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2011-06-03 English
4 Filing
Director's Dealing
2011-06-03 English
4 Filing
Director's Dealing
2011-06-03 English
8-K Filing
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports on a material definitive agreement (a License Agreement) entered into by the company, Ligand Pharmaceuticals, and details related financial obligations and contingent value rights. The content focuses on a specific event and contractual details rather than comprehensive financial results or annual/quarterly reporting. Form 8-K filings are typically categorized as Regulatory Filings (RNS) because they are event-driven disclosures rather than full financial reports or presentations. The document length (7010 characters) and content confirm it is a standalone event report, not an annual or quarterly report, earnings release, or other specific category. Therefore, the appropriate classification is Regulatory Filings (RNS).
2011-06-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.